![Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study](https://pub.mdpi-res.com/cancers/cancers-13-02797/article_deploy/html/images/cancers-13-02797-g001.png?1622795847)
Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial - Annals of Oncology
![Cancers | Free Full-Text | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients Cancers | Free Full-Text | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients](https://pub.mdpi-res.com/cancers/cancers-12-01131/article_deploy/html/images/cancers-12-01131-g001-550.jpg?1590669585)
Cancers | Free Full-Text | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
![Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-018-0784-z/MediaObjects/12325_2018_784_Fig1_HTML.png)
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy
![NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial - The Lancet NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/807543d1-657d-4cc8-ab40-d2c979b54419/gr1.jpg)
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial - The Lancet
![Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022 Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022](https://journals.sagepub.com/cms/10.1177/10781552211038677/asset/images/large/10.1177_10781552211038677-fig1.jpeg)
Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022
![PDF] Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+ Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results | Semantic Scholar PDF] Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+ Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6ccc8cdf39296959027d84f941ad1c4ed3660ed0/3-Figure1-1.png)
PDF] Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+ Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results | Semantic Scholar
![Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine](https://www.thelancet.com/cms/attachment/261f21cd-efcc-464c-8685-2736792db058/gr1_lrg.jpg)
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
![Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly - The ASCO Post Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly - The ASCO Post](https://ascopost.com/media/2974/60204_chart.jpg)
Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly - The ASCO Post
![Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer](https://pub.mdpi-res.com/life/life-12-00327/article_deploy/html/images/life-12-00327-ag-550.jpg?1645693413)
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
![A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer | Nature Communications A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-31704-7/MediaObjects/41467_2022_31704_Fig1_HTML.png)
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer | Nature Communications
![Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/e2916075-4a0f-4aac-8bbd-8817585876bd/gr1.gif)
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
![A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921011655-ga1.jpg)
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect
![Frontiers | The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy Frontiers | The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy](https://www.frontiersin.org/files/Articles/688377/fonc-11-688377-HTML/image_m/fonc-11-688377-g001.jpg)
Frontiers | The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
![Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation - International Journal of ... Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation - International Journal of ...](https://www.redjournal.org/cms/asset/40fc8a4b-a1dc-4631-a5db-4f6275e37cbf/gr1.jpg)
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation - International Journal of ...
![Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab- paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab- paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology](https://mednexus.org/cms/10.1097/JP9.0000000000000038/asset/c28bb572-1302-4653-9250-7ce30dad7578/assets/graphic/2096-5664-03-01-005-f001.png)
Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab- paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology
![Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2011.36.5742/asset/images/zlj9991016430002.jpeg)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology
![Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine: Molecular Therapy - Oncolytics Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/3196df8f-7524-468a-adf1-5a8472924e03/gr1.jpg)
Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine: Molecular Therapy - Oncolytics
![Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2059702920326375-gr1.jpg)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect
![Overview | GABARNANCE TRIAL: Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer Overview | GABARNANCE TRIAL: Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer](https://gabarnance.jp/content/images/en/overview_1.png)
Overview | GABARNANCE TRIAL: Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer
![Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate](https://ascpt.onlinelibrary.wiley.com/cms/asset/ca474d8a-3b8b-4de4-8388-e0d7e5ca1f1d/cts13661-fig-0002-m.jpg)
Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate
![Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study | BMC Cancer Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study | BMC Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-021-08275-9/MediaObjects/12885_2021_8275_Fig1_HTML.png)
Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study | BMC Cancer
![Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921001064-gr1.jpg)
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect
![Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial ... Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial ...](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13063-015-1101-7/MediaObjects/13063_2015_1101_Fig1_HTML.gif)